or Try an Advanced Search...

    Technical Analysis for PBYI - Puma Biotechnology Inc

    Grade Last Price % Change Price Change
    D 5.13 -0.77% -0.04
    PBYI closed down 0.77 percent on Tuesday, April 23, 2024, on 46 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 2
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical PBYI trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish -0.77%
    Bollinger Band Squeeze Range Contraction -0.77%
    Oversold Stochastic Weakness -0.77%
    Bollinger Band Squeeze Range Contraction 2.40%
    BB Squeeze + Lower Band Touch Range Contraction 2.40%
    Lower Bollinger Band Touch Weakness 2.40%
    Oversold Stochastic Weakness 2.40%
    Older End-of-Day Signals for PBYI ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 8 hours ago
    Down 1% about 8 hours ago
    Possible NR7 about 10 hours ago
    60 Minute Opening Range Breakout about 13 hours ago
    Rose Above Previous Day's High about 13 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PBYI Chart by TradingView
    Basic chart:

    Profile

    Puma Biotechnology Inc Description

    Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Organic Compounds Breast Cancer Chemical Compounds Non Small Cell Lung Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Signal Transduction Tyrosine Kinase Her2 Chloroarenes Her2/Neu Pyridines Advanced Breast Cancer Advanced Cancer Nitriles

    Is PBYI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
    Apr 8 Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year
    Mar 22 Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
    Mar 22 Do Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention?
    Mar 20 Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.
    Mar 20 Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
    Mar 18 Puma Biotechnology dips after dismissal of its suit was granted by a federal judge
    Mar 5 Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation
    Mar 5 FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
    Mar 4 J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
    See more PBYI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.73
    52 Week Low 2.13
    Average Volume 643,995
    200-Day Moving Average 4.15
    50-Day Moving Average 5.64
    20-Day Moving Average 5.36
    10-Day Moving Average 5.22
    Average True Range 0.34
    RSI (14) 45.05
    ADX 10.99
    +DI 21.02
    -DI 20.30
    Chandelier Exit (Long, 3 ATRs) 5.03
    Chandelier Exit (Short, 3 ATRs) 5.92
    Upper Bollinger Bands 5.82
    Lower Bollinger Band 4.91
    Percent B (%b) 0.25
    BandWidth 16.96
    MACD Line -0.09
    MACD Signal Line -0.06
    MACD Histogram -0.0322
    Fundamentals Value
    Market Cap 244.04 Million
    Num Shares 47.6 Million
    EPS 0.07
    Price-to-Earnings (P/E) Ratio 73.29
    Price-to-Sales 1.20
    Price-to-Book 7.09
    PEG Ratio 0.03
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.49
    Resistance 3 (R3) 5.52 5.43 5.43
    Resistance 2 (R2) 5.43 5.34 5.42 5.41
    Resistance 1 (R1) 5.28 5.28 5.24 5.25 5.39
    Pivot Point 5.19 5.19 5.17 5.18 5.19
    Support 1 (S1) 5.04 5.10 5.00 5.01 4.87
    Support 2 (S2) 4.95 5.04 4.94 4.85
    Support 3 (S3) 4.80 4.95 4.83
    Support 4 (S4) 4.77